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Abstract
Background Electronic medical records and insurance
claims data from the Geisinger Health System were examined
to assess the real-world healthcare costs of being overweight
or obese at different glycemic stages, including normal gly-
cemia, pre-diabetes (PreD), and type 2 diabetes (T2D).
Methods The medical history of the sample subjects was
segmented into different glycemic stages via diagnosis
codes, glycosylated hemoglobin A1c or fasting plasma
glucose laboratory results, and use of antidiabetic drugs.
Healthcare resource utilization captured by the claims and
associated costs (in 2013 values) were examined for each
glycemic stage. The association between costs and body
mass index (BMI) was estimated by regressions, and
adjusted for sociodemographics. We predicted the adjusted
incremental annual costs associated with high BMI, rela-
tive to normal BMI (18.5–24.9 kg/m2).
Results We identified 48,344 adults in normal glycemic
stage, 3,085 in the PreD stage, and 9,526 in the T2D stage
(mean age 46, 58, and 60 years, respectively; mean BMI
29, 32, and 33 kg/m2, respectively). The adjusted incre-
mental annual costs associated with high BMI relative to
normal BMI ranged from $336 for overweight
(25–29.9 kg/m2) to $1,850 for class III obesity (C40 kg/
m2) during normal glycemic stage; were only significant
for class III ($2,434) during the PreD stage; and ranged
from $1,139 for overweight to $4,649 for class III during
the T2D stage (all p\ 0.05).
Conclusions Positive associations between healthcare
costs and BMI levels were observed within each glycemic
stage. Management of body weight is important in reducing
the overall healthcare costs, especially for subjects with PreD
or T2D.
Key Points for Decision Makers
Based on a regional US claims dataset, positive
associations between total healthcare costs and BMI
levels were observed within each glycemic stage.
Overweight and obese subjects (BMI C25 kg/m2)
had higher costs than those with normal BMI in both
the normal glycemic stage and the type 2 diabetes
(T2D) stage, while during the pre-diabetes (PreD)
stage, subjects with extreme obesity (BMI C40 kg/
m2) had higher costs.
The costs of being overweight and obese, relative to
normal BMI (18.5–24.9 kg/m2), were much higher
among subjects with T2D than those with normal
glycemic levels. Extreme obesity had a noticeable
impact on healthcare costs within each glycemic
stage.
Targeted weight-control programs aimed at people
with PreD, or at-risk normal glycemic subjects, as
well as those with frank T2D, should be able to
generate a significant return on investment by
effectively reducing the economic burden of
overweight and obesity in the US.
Q. Li (&)  S. W. Blume
Retrospective Observational Studies, Evidera, 430 Bedford
Street, Suite 300, Lexington, MA 02420, USA
e-mail: qian.li@evidera.com
J. C. Huang  M. Hammer
Health Economics and Outcomes Research, Novo Nordisk Inc,
Plainsboro, NJ, USA
T. R. Graf




Obesity, a disease classified as body mass index (BMI)
C30 kg/m2, has become a major public health problem in the
US, affecting over one-third (35.7 %) of the population [1].
Being overweight or obese is a risk factor for numerous costly
co-morbidities, such as metabolic diseases, cardiovascular
diseases, and certain types of cancers [2]. Annual spending
related to obesity and its associated comorbidities is estimated
to be $315.8 billion in 2010, accounting for 27.5 % of US
healthcare expenditures [3]. Costs related to being overweight
or obese are projected to reach $861 billion in 2030 [4].
Obesity is strongly associated with pre-diabetes (PreD)
and type 2 diabetes (T2D). Diabetes, a chronic metabolic
disorder characterized by hyperglycemia, affected
approximately 9 % (29 million) of the US population in
2012 [5]. In addition, 37 % (81 million) of Americans aged
20 years and older had PreD [6]. Diabetes was responsible
for direct medical costs of $176 billion in 2012 [7]. T2D
comprises approximately 90–95 % of all diabetes cases [6].
Obesity is one of the most common risk factors for T2D,
and T2D is one of the most common obesity-related co-
morbidity [8]. The risk of developing T2D has been
reported to increase by 6.7-fold compared with normal
BMI for male obese patients, and 12.4-fold for female
obese patients [2]. In fact, management of body weight is
also a key factor in the successful management of T2D [9].
More than 60 % of patients with T2D are obese [10] and
approximately 57 % of the total costs of T2D are attrib-
utable to obesity [11]. The impact of obesity on T2D
extends to patients with PreD. Higher BMI is associated
with a higher risk of developing PreD and accelerates the
progression from PreD to T2D [12]. Obesity at least par-
tially explains the increased costs in patients with PreD
compared with subjects with normal glycemia [13].
The assessment of the economic burden of overweight and
obesity given a person’s diabetes status could be an infor-
mative and useful tool in the decision-making process on cost-
effective strategies for the prevention and management of
obesity, as considered by various healthcare providers and
policy makers, but the quantitative data are scarce. The
objective of this study was to help fill this gap in the literature
and evaluate the healthcare costs in the US of being over-
weight or obese at different glycemic stages, including the
normal glycemic stage (i.e. euglycemia), PreD, and T2D.
2 Methods
2.1 Data Source
Data were obtained from the MedMining database, which
contains electronic medical records (EMRs) from the
Geisinger Health System, an integrated health system
serving northern Pennsylvania with 880? multispecialty
physician group practices, 5 hospital campuses, 72 primary
and specialty clinic sites, and a health plan. Health records,
which have been kept in electronic form at the Geisinger
Health System since 1996, cover over 4 million subjects
and contain information on demographic characteristics
(age, sex, and race/ethnicity), encounter details from
inpatient, outpatient, and office-based settings (including
diagnostic and procedure codes), medication orders, vital
signs, laboratory results, and actual costs incurred by the
Geisinger Health System for those encounters.
Claims-level data are available for the subset of patients
who are enrolled in the Geisinger Health Plan (GHP) and
are linked to the EMR data. The GHP claims data include
the claims records for all eligible GHP members for all
services (including medical services and prescription fills).
The GHP enrollees are covered by various types of insur-
ance (46 % are covered by a health maintenance organi-
zation (HMO), 34 % by a preferred provider organization
(PPO), 11 % by a Medicare HMO, 3 % by a Medicare
PPO, and 6 % by other types).
2.2 Study Design
A cross-sectional study design was used to examine the
association between BMI and healthcare costs during each
glycemic stage. The analyses were conducted separately
for normal glycemia, PreD, and T2D stages. One individual
could have multiple glycemic stages over time due to
transitions between stages, and thus could be included in
multiple analyses.
2.3 Sample Selection
The base study population, from MedMining EMRs and
claims data between January 2004 and May 2013, was
required to meet all of the following inclusion criteria: (1)
C2 years’ enrollment in the GHP; (2) non-null BMI (or
weight and height) value; (3) age C18 years; and (4) no
diagnosis codes of type 1 diabetes (International Classifi-
cation of Diseases, Ninth Revision, Clinical Modification
[ICD-9-CM]: 250.x1, 250.x3) or secondary diabetes (ICD-
9-CM: 249.xx). The base study population contained
153,561 subjects. Due to data size restriction, we could
obtain a total sample of up to 100,000 subjects from the
MedMining dataset. We first selected all subjects with
potential PreD or T2D stages (Part I sample) from the base
study population, i.e. all patients with glycemic laboratory
tests (fasting plasma glucose [FPG] or glycosylated
hemoglobin [HbA1c]), T2D diagnosis (ICD-9-CM: 250.x0,
250.x2), or use of antidiabetic medications. There were
43,639 subjects in the Part I sample. The remaining
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subjects in the base study population, not meeting any of
the Part I sample criteria, are assumed to have normal
glycemic status. We randomly selected a 51 % sample of
these subjects (Part II sample) up to our subject number
limit.
Subjects (both Part I and Part II samples) were excluded
from the study if, during the longest continuous enrollment
in the GHP plan and up until any pregnancy (the study
period), they had (1) \2 years of data; (2) evidence of
underweight (BMI\18.5 kg/m2); (3) conditions associated
with unintentional weight change (malignancy, human
immunodeficiency virus, cachexia, anorexia, abnormal
weight gain or loss, feeding difficulties, gastrointestinal
disorders, inflammatory bowel diseases, pancreatitis, and
nutritional deficiencies with the exception of vitamin
deficiency); or (4) bariatric surgery since the dramatic
weight reduction and high costs associated with the surgery
may bias the association between BMI and costs.
2.4 Glycemic Stage Identification
Data between January 2004 and May 2013 were examined
to identify the glycemic stages for each subject, as shown
in Fig. 1. T2D, being the end-stage of the glycemic con-
tinuum, was first identified by at least one diagnosis code of
250.x0 or 250.x2, or at least two laboratory results of
HbA1c C6.5 % and/or FPG C126 mg/dL, or any use of
non-metformin antidiabetic medications. Before the
occurrence of T2D, or if T2D was not found throughout the
entire data, PreD was searched and defined as at least one
laboratory result of HbA1c 5.7–6.4 % and/or FPG
100–126 mg/dL. Last, subjects were considered to be in
the normal glycemic stage (without a preceding history of
PreD or T2D) if they had C2 years of continuous enroll-
ment without laboratory results beyond normal glycemic
level and without use of antidiabetic medications. The
laboratory result cutoffs to define PreD and T2D follow the
American Diabetes Association recommendations [9].
For each glycemic stage, the data during the study
period were analyzed and referred to as the follow-up
period. In addition to the sample selection criteria above,
subjects were required to have C1 year of follow-up period
with at least one BMI value.
2.5 Study Measures
Patient demographics were measured at the start of the
follow-up period during a glycemic stage, and included
age, sex, race, smoking, employment status, insurance
type, and year to start follow-up (from 2004 to 2011). The
mean BMI values during a follow-up period were exam-
ined and categorized into five levels according to the WHO
classification: 18.5 B BMI\ 25 kg/m2 (normal BMI),
25 B BMI\ 30 kg/m2 (overweight), 30 B BMI\ 35 kg/
m2 (class I obesity), 35 B BMI\ 40 kg/m2 (class II
obesity), and BMI C40 kg/m2 (class III obesity) [14].
The healthcare resource utilization in the follow-up
period during a glycemic stage, as recorded by the GHP
claims data, was classified by type of service, including
inpatient hospitalizations, outpatient services, and outpa-
tient pharmacy prescriptions. The number of total services
received and length of inpatient stays were examined. To
measure healthcare costs, unit costs from external sources
[15–17] were assigned to GHP claims as financial
amounts were not released by Geisinger. Inpatient stays
recorded in the GHP claims data were matched to costs
reported in the Healthcare Cost and Utilization Project
(HCUP) survey (2010 data) according to diagnosis code,
region, and length of stay [17]. Health services in out-
patient settings (including physician services [18], clinical
laboratory services [19], ambulance services [20], and the
use of durable medical equipment [21] associated with
physician office, emergency room, hospital outpatient,
and other outpatient visits) were mapped to costs reported
in the Centers for Medicare & Medicaid Services (CMS)
2012 fee-for-service fee schedules according to Health-
care Common Procedure Coding System (HCPCS) pro-
cedure codes [16]. Pharmacy costs were estimated based
on average wholesale price from Truven Health Analyt-
ics’ Red BookTM [15]. Costs were adjusted to 2013 dol-
lars using the US Medical Consumer Price Index [22].
Due to the variable duration of the follow-up period,
Fig. 1 Glycemic staging. PreD pre-diabetes, T2D type 2 diabetes
The Economic Burden of Obesity 737
utilization and cost measures were standardized as annual
utilization and costs.
2.6 Statistical Analysis
The analyses were conducted separately for each glyce-
mic stage. Descriptive statistics of all study measures
were reported and stratified by BMI categories. The
association between the BMI categories and the costs
(total healthcare costs, inpatient costs, outpatient costs,
and pharmacy costs) was assessed by multivariable
regressions, adjusting for demographics. The regressions
were generalized linear regression models with log-link
and gamma distribution, which can estimate the adjusted
ratios of costs associated with high BMI categories (from
overweight to class III obesity) versus normal BMI level.
The scaled deviance was used to assess the goodness of fit
of the models [23]. The adjusted incremental total costs
were also estimated for each of the high BMI categories
relative to normal BMI level, such that adjusted costs
were predicted by assuming all sample subjects were in
one BMI level and the average change in adjusted costs
between BMI levels was calculated [24]. In all the
regression analyses, subjects in the Part II sample were
assigned a uniform sampling weight representing their
true proportion in the base population. Specifically, each
subject in the Part II sample was considered to represent
1.96 subjects (i.e. inverse of the 51 % sampling fraction).
Analyses were performed using SAS software version 9.2
(SAS Institute, Cary, NC, USA).
3 Results
3.1 Study Sample and Characteristics
The final study sample, as shown in Fig. 2, contained
48,344 subjects (representing 81,983 subjects after
weighting) in the normal glycemic stage, 3,085 in the
PreD stage, and 9,526 in the T2D stage. Individual
characteristics in each glycemic stage, stratified by BMI
category, are described in Table 1. The mean BMI was
29.4, 32.4, and 33.2 kg/m2 during the normal glycemic,
PreD, and T2D stages, respectively. The mean duration of
follow-up was 5.2, 3.1, and 4.6 years, respectively. The
duration was stable across BMI categories within each
glycemic stage.
Subjects were approximately 10 years younger at the
start of follow-up during the normal glycemic stage than
those progressing to the PreD or T2D stages (46.2 vs. 57.6
or 59.8 years of age). The age of subjects in the normal
glycemic stage remained approximately the same
regardless of their BMI. However, the age of subjects in
the PreD and T2D stages declined as the BMI increased.
3.2 Descriptive Analysis of Healthcare Resource
Utilization and Costs
Table 2 presents the annualized healthcare resource utili-
zation and costs in each glycemic stage. During the normal
glycemic stage, one hospitalization occurred per ten sub-
jects per year, with an average stay of 1.9 days. Subjects
during the normal glycemic stage averaged 9.1 outpatient
visits and 11.8 prescription fills per year. The use of
inpatient services was stable across BMI categories but the
use of outpatient services and pharmacy fills increased with
BMI. The healthcare utilization translates to an average
$4,467 in healthcare costs (median $2,022) per person per
year during the normal glycemic stage. The mean health-
care costs were divided equally among inpatient, outpa-
tient, and pharmacy across BMI categories.
Healthcare resource utilization was much higher during
the PreD stage than the normal glycemic stage. The annual
healthcare costs were, on average, $9,342 (median $4,608).
For the normal BMI subjects with PreD, inpatient costs
accounted for the most costs (53.2 %) and pharmacy costs
accounted for the least (21.9 %). The contribution of
inpatient costs was lower at higher levels of BMI, while the
contribution of pharmacy costs increased. For class III
obesity in PreD subjects, healthcare costs came least from
inpatient services (23.0 %) and most from pharmacy fills
(43.0 %).
Subjects with T2D had higher healthcare resource uti-
lization than those with PreD, especially in the number of
pharmacy fills (mean 32.2), which increased with higher
BMI. The annual healthcare costs were, on average,
$11,983 (median $6,811). Inpatient costs were the largest
component (50.4 %) for normal BMI, but had similar
contribution as pharmacy costs (*37 %) for class III
obesity.
3.3 Regression Analysis of Costs
With adjustment for demographics, the ratio of costs
associated with each BMI category versus normal BMI
is presented in Table 3. The cost ratios associated with
all the covariates are presented in Table 4 Appendix.
The regression models fit the data reasonably well, with
scaled deviances close to 1 (Table 4 Appendix). During
the normal glycemic stage, the ratio of annual total costs
increased from 1.09 (95 % confidence interval [CI]
1.07–1.11) for overweight BMI to 1.51 (1.45–1.56) for
class III obesity. The cost ratio also increased with BMI
for all the cost components (all p\ 0.05). During the
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PreD stage, only class III obesity was associated with
higher total costs than normal BMI (1.28 [1.09–1.51]),
and it also had higher outpatient costs (1.26 [1.10–1.44])
and pharmacy costs (1.48 [1.16–1.89]). Higher outpatient
costs were also observed for class I obesity (1.22
[1.09–1.37]). During the T2D stage, all the BMI levels
higher than normal BMI were associated with higher
costs, and the cost ratio increased with BMI, from 1.11
(1.03–1.20) for overweight BMI to 1.46 (1.34–1.59) for
class III obesity. The cost ratio of outpatient costs and
pharmacy costs also increased with BMI. For inpatient
costs, only class III obesity had statistically significant
higher costs than normal BMI, with a cost ratio of 1.60
(1.27–2.01).
The adjusted cost ratios were translated to incre-
mental costs, as illustrated in Fig. 3. For subjects with
normal glycemia, the incremental annual total costs
associated with overweight or obesity relative to normal
BMI ranged from $336 for overweight to $1,850 for
class III obesity (all p\ 0.05). Among the cost com-
ponents, the largest incremental costs were from inpa-
tient services associated with class III obesity ($1,084;
p\ 0.05). For subjects in the PreD stage, the incre-
mental annual total costs associated with overweight or
obesity relative to normal BMI ranged from $792 for
overweight to $2,432 for class III obesity, and were only
significant for class III obesity. This was mainly
reflected by the incremental pharmacy costs ($1,165).
For subjects in the T2D stage, the annual incremental
total costs relative to normal BMI were significant and
ranged from $1,139 for overweight to $4,649 for class
III obesity (all p\ 0.05). Inpatient costs associated with
class III obesity ($2,629) had the largest incremental
costs among the cost components.
Fig. 2 Sample selection.
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4 Discussion
Based on a regional US claims dataset, our study observed
significantly increased healthcare costs with higher BMI
level compared with normal BMI, after adjusting for so-
ciodemographics. The positive associations varied by gly-
cemic stage. The incremental costs of being overweight
and obese were much higher among subjects with T2D
than those with normal glycemic levels. Extreme obesity
had a noticeable impact on healthcare costs regardless of
the glycemic stages.
The economic burden of overweight and obesity has
been well studied in the US. A systematic review on ret-
rospective database studies published before 2009 esti-
mated the direct medical costs of overweight and obesity
were $266 and $1,723, respectively, per person per year
(2008 US$) [25]. Recent assessments mostly utilized
insurance claims data from large employers [26–28]. Data
Table 1 Demographics by BMI in each glycemic stage
All 18.5 B BMI\25 25 B BMI\ 30 30 B BMI\ 35 35 B BMI\ 40 40 B BMI
Normal glycemic stage
No. of subjects (%) 48,344 (100) 11,655 (24) 17,674 (37) 11,243 (23) 4,862 (10) 2,910 (6)
BMI [mean (SD)] 29.4 (6.1) 22.8 (1.5) 27.4 (1.4) 32.2 (1.4) 37.1 (1.4) 44.8 (4.7)
Follow-up duration [years; mean (SD)] 5.2 (2.3) 5.1 (2.3) 5.3 (2.4) 5.3 (2.3) 5.1 (2.3) 4.9 (2.2)
Stage starting since 2004 (%) 59.6 59.6 57.4 60.2 60.9 59.8
Age [mean (SD)] 46.2 (15.3) 43.4 (16.2) 47.5 (15.5) 47.5 (14.5) 46 (14.1) 44.2 (13)
Male (%) 47.9 34.8 55.0 54.7 45.4 36.0
White (%) 97.7 96.8 97.6 98.2 98.5 98.3
Current smoker (%) 21.2 24.9 21.0 20.3 17.6 16.6
Full-time employment (%) 60.7 57.7 59.9 62.0 63.9 67.7
Covered by HMO plans (%) 82.9 81.6 83.1 83.5 83.9 82.3
PreD stage
No. of subjects (%) 3,085 (100) 309 (10) 963 (31) 925 (30) 498 (16) 390 (13)
BMI [mean (SD)] 32.4 (6.9) 23.2 (1.4) 27.6 (1.4) 32.3 (1.4) 37.3 (1.5) 45.8 (5.3)
Follow-up duration [years; mean (SD)] 3.1 (1.8) 3.0 (1.7) 3.3 (1.8) 3.1 (1.7) 3.1 (1.7) 3.0 (1.8)
Stage starting since 2004 (%) 8.2 5.5 7.4 9.7 7.0 10.5
Age [mean (SD)] 57.6 (13.7) 62.1 (15.4) 60.3 (13.4) 58.4 (13.0) 53.6 (12.5) 50.2 (12.2)
Male (%) 47.7 41.1 55.8 50.7 44.4 30.3
White (%) 97.3 95.1 96.9 97.4 98.4 98.2
Current smoker (%) 17.5 25.6 19.8 14.1 15.5 15.9
Full-time employment (%) 48.7 40.8 43.3 46.1 57.6 63.3
Covered by HMO plans (%) 87.3 83.8 89.1 89.0 83.7 86.4
T2D stage
No. of subjects (%) 9,526 (100) 776 (8) 2,672 (28) 2,874 (30) 1,810 (19) 1,394 (15)
BMI [mean (SD)] 33.2 (6.9) 23.2 (1.4) 27.7 (1.4) 32.4 (1.4) 37.2 (1.4) 45.6 (5.2)
Follow-up duration [years; mean (SD)] 4.6 (2.3) 4.5 (2.3) 4.7 (2.3) 4.7 (2.3) 4.6 (2.3) 4.3 (2.2)
Stage starting since 2004 (%) 32.5 32.3 33.8 33.2 32.6 28.5
Age [mean (SD)] 59.8 (13.2) 64.8 (14.8) 63.7 (12.7) 60.2 (12.6) 56.6 (12.1) 53.2 (12.3)
Male (%) 51.0 42.8 54.5 54.8 50.9 41.0
White (%) 97.7 95.1 97.2 97.9 98.4 98.6
Current smoker (%) 14.6 17.4 14.6 14.4 13.8 14.6
Full-time employment (%) 39.0 28.0 31.4 38.7 45.4 52.2
Covered by HMO plans (%) 85.7 85.4 87.4 87.0 85.0 81.1
The study measures were created for the analysis in each glycemic stage separately. Patient demographics were measured at the start of the
glycemic stage and included age, sex, race (White, Black, and other), smoking status (never smoked, former smoker, current smoker, and other),
employment status (full-time employed, not employed, and other), insurance type (HMO plans or other), and year with the start of the glycemic
stage (from 2004 to 2011)
BMI body mass index, HMO health maintenance organization, PreD pre-diabetes, SD standard deviation, T2D type 2 diabetes
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Table 2 Annualized healthcare utilization and costs in each glycemic stage
All 18.5 B BMI\25 25 B BMI\30 30 B BMI\35 35 B BMI\40 40 B BMI
Normal glycemic stage
No. of patients 48,344 11,655 17,674 11,243 4,862 2,910
No. of hospitalizations
[mean (SD)]
0.1 (0.2) 0.1 (0.2) 0.1 (0.2) 0.1 (0.2) 0.1 (0.2) 0.1 (0.3)
Length of stay (days) if
hospitalized [mean (SD)]
1.9 (3.2) 2.1 (3.8) 1.9 (3.3) 1.8 (2.7) 1.7 (2.4) 2.1 (4.4)
No. of outpatient visits
[mean (SD)]
9.1 (8.3) 8.3 (7.9) 9 (8.3) 9.6 (8.5) 10 (8.7) 10.3 (8.9)
No. of pharmacy fills [mean (SD)] 11.8 (15.3) 9.8 (13.3) 11.3 (14.9) 12.9 (15.9) 14.2 (17.1) 15.5 (17.8)












Distribution of costs by setting (%)
Inpatient costs 31.3 31.2 32.3 31.0 28.0 32.9
Outpatient costs 35.6 37.1 35.3 35.1 36.6 32.8
Pharmacy costs 33.1 31.7 32.4 33.9 35.4 34.3
PreD stage
No. of patients 3,085 309 963 925 498 390
No. of hospitalizations
[mean (SD)]
0.2 (0.5) 0.3 (0.6) 0.2 (0.6) 0.2 (0.5) 0.1 (0.4) 0.1 (0.3)
Length of stay (days) if hospitalized
[mean (SD)]
4.0 (6.8) 5.5 (9.8) 4.3 (7.6) 3.8 (5.6) 3.0 (5.0) 2.7 (3.8)
No. of outpatient visits
[mean (SD)]
15.7 (12.2) 16.3 (12.9) 16 (12.3) 15.8 (12.7) 14.5 (11.2) 15.5 (11.8)
No. of pharmacy fills
[mean (SD)]
24.3 (24.3) 21.4 (22.6) 24.0 (24.3) 25.3 (24.4) 24.8 (25.8) 24.4 (23.1)














Distribution of costs by setting (%)
Inpatient costs 37.5 53.2 43.2 34.5 27.6 23.0
Outpatient costs 30.9 24.9 27.8 34.7 33.2 34.0
Pharmacy costs 31.6 21.9 28.9 30.8 39.2 43.0
T2D stage
No. of patients 9,526 776 2,672 2,874 1,810 1,394
No. of hospitalizations [mean (SD)] 0.2 (0.5) 0.3 (0.7) 0.3 (0.6) 0.2 (0.5) 0.2 (0.5) 0.2 (0.5)
Length of stay (days) if
hospitalized [mean (SD)]
3.8 (6.8) 4.5 (7) 4.1 (7.7) 3.4 (6.1) 3.5 (6.1) 3.7 (7.2)
No. of outpatient visits [mean (SD)] 18.6 (13) 18.7 (13.6) 18.8 (13.2) 18.5 (12.5) 18.4 (13) 19 (13.1)
No. of pharmacy fills [mean (SD)] 32.2 (27.3) 27.8 (25.2) 29.6 (25.8) 32.2 (26.8) 34.0 (28.2) 37.7 (30.1)














Distribution of costs by setting (%)
Inpatient costs 41.5 50.4 46.1 39.7 36.6 37.4
Outpatient costs 26.6 25.2 26.0 27.7 27.5 25.5
Pharmacy costs 31.8 24.4 28.0 32.6 35.9 37.1
Mean of the annualized healthcare resource utilization and costs represented the average utilization and costs per person per year
BMI body mass index, PreD pre-diabetes, SD standard deviation, SE standard error, T2D type 2 diabetes
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from 2003–2011 reported that the adjusted annual health-
care costs for obese employees were $2,055 higher than for
those with BMI less than 27 kg/m2 [26]. Another study
estimated that the incremental annual healthcare costs,
compared with normal BMI, were $147, $712, and $1,977
(2005 US$) for overweight, obese, and class II–III obese
(BMI C35 kg/m2), respectively, among employees from
2003–2005 [29]. Overall, the literature on the general
overweight and obese population compares well with our
study’s estimates of incremental BMI costs for the normal
glycemic stage.
Despite the importance of weight control for subjects
with PreD or T2D, there are limited studies on the cost of
obesity for this specific population. Data from Germany
found that obesity was associated with significant incre-
ments in the healthcare costs among adult patients with
T2D, adjusted for age, sex, and diabetes complications
[30]. No previous study has been found to evaluate the cost
consequence of weight gain for subjects with PreD. In our
study, the positive association between healthcare costs and
BMI during the PreD stage was only significant for the
extreme obesity level. This may be due to the small sample
size and short duration of the identified PreD stage. Nev-
ertheless, weight control among subjects with PreD is
crucial. A clinical trial has shown that, compared with no
intervention or use of metformin only, weight loss is
associated with significantly slower progression from PreD
to T2D [31].
It would be interesting to explore the underlying drivers
of the positive association between costs and BMI levels.
Existing literature indicates that obesity-related co-mor-
bidities, such as diabetes, hypertension, and coronary heart
disease, contribute to the majority, if not all, of the eco-
nomic burden of obesity [32]. Even after controlling for
diabetes, one of the most common and costly co-morbidi-
ties of obesity, our study still observed higher healthcare
costs for higher BMI levels.
In terms of healthcare settings, our study found that,
during normal glycemic stage and T2D stage, incremental
pharmacy costs for BMI between 25 and 40 kg/m2 were
higher than incremental inpatient costs and incremental
outpatient costs, while for extreme obesity (BMI C40 kg/
m2), the largest incremental costs occurred in the inpatient
setting. During the PreD stage, the economic burden of
obesity was mainly from pharmacy costs associated with
extreme obesity. The importance of pharmacy costs is, at
least in part, due to the fact that obesity-related co-mor-
bidities are chronic conditions which rely heavily on pre-
scription medication treatment.
The demographics, measured at the start of the follow-
up period, varied across BMI levels. During PreD and T2D
stages, subjects with higher BMI level were much younger.
This implies that subjects with high BMI progress to PreD
or T2D at a younger age. Our study examined the mean
BMI during the glycemic stage in order to summarize the
overall BMI status and assess its association with the
healthcare costs. In our study sample, approximately 30 %
of subjects changed BMI level. Further research could be
conducted to analyze how the variation of BMI affects the
healthcare costs.
Table 3 Cost ratio of annualized costs, relative to 18.5 B BMI\ 25, in each glycemic stage
25 B BMI\ 30 30 B BMI\ 35 35 B BMI\ 40 40 B BMI
Normal glycemic stage
Total healthcare costs 1.09 (1.07–1.11) 1.25 (1.22–1.27) 1.30 (1.26–1.34) 1.51 (1.45–1.56)
Inpatient costs 1.11 (1.06–1.16) 1.35 (1.29–1.43) 1.41 (1.32–1.51) 2.06 (1.89–2.24)
Outpatient costs 1.05 (1.03–1.06) 1.15 (1.13–1.17) 1.23 (1.20–1.26) 1.28 (1.24–1.32)
Pharmacy costs 1.16 (1.13–1.20) 1.33 (1.29–1.38) 1.36 (1.30–1.42) 1.47 (1.40–1.56)
PreD stage
Total healthcare costs 1.09 (0.95–1.25) 1.09 (0.95–1.25) 1.04 (0.90–1.22) 1.28 (1.09–1.51)
Inpatient costs 1.23 (0.86–1.76) 1.01 (0.71–1.45) 0.89 (0.59–1.33) 1.15 (0.75–1.75)
Outpatient costs 1.09 (0.98–1.23) 1.22 (1.09–1.37) 1.09 (0.96–1.24) 1.26 (1.10–1.44)
Pharmacy costs 1.20 (0.98–1.46) 1.19 (0.97–1.45) 1.24 (1.00–1.56) 1.48 (1.16–1.89)
T2D stage
Total healthcare costs 1.11 (1.03–1.20) 1.17 (1.09–1.27) 1.29 (1.19–1.40) 1.46 (1.34–1.59)
Inpatient costs 1.11 (0.91–1.37) 1.09 (0.89–1.34) 1.20 (0.96–1.49) 1.60 (1.27–2.01)
Outpatient costs 1.11 (1.04–1.18) 1.17 (1.09–1.25) 1.22 (1.14–1.31) 1.27 (1.18–1.37)
Pharmacy costs 1.14 (1.02–1.27) 1.26 (1.13–1.40) 1.40 (1.24–1.57) 1.48 (1.31–1.67)
Cost ratios were estimated from generalized linear regression models with log-link and gamma distribution, adjusted for age, sex, race, smoking,
employment status, insurance type, and year to start follow-up. The parentheses contain the 95 % confidence intervals of the cost ratios
BMI body mass index, PreD pre-diabetes, T2D type 2 diabetes
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Our study used a cross-sectional study design to provide
a snapshot assessment on the association between BMI and
healthcare costs during the entire glycemic stage. The
longitudinal feature of the data may complicate the
assessment and thus requires a more advanced analysis
approach. For example, a fixed-effect model with panel
study design could account for individual heterogeneity
effects. However, due to the chronic nature of obesity, the
lack of variation of BMI makes it challenging to apply the
comment panel data approaches. In addition, our study
sample had, on average, 3–5 years of follow-up, and thus
medical innovations in recent years may affect the cost and
BMI association, especially for patients with T2D.
It is challenging to identify the glycemic stages in a
retrospective database which usually has no requirement
for periodic glycemic testing. This particularly affects our
recognition of PreD as it can be determined only by lab-
oratory values. The differences in patient demographics
Fig. 3 Adjusted incremental annualized costs, relative to
18.5 B BMI\ 25, in each glycemic stage. Incremental costs were
adjusted for age, sex, race, smoking status, employment status,
insurance type, and year starting the stage. Underscored incremental
costs had p\ 0.05 compared with normal BMI, based on generalized
linear regression model with log-link and gamma distribution. BMI
body mass index, PreD pre-diabetes, T2D type 2 diabetes
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and economic outcomes between PreD and T2D were
smaller than that between normal glycemic stage and PreD,
which indicates that PreD in our study may not be identi-
fied until close to its progression to diabetes. For subjects
with no FPG or HbA1c laboratory results, diagnosis of
T2D, or use of antidiabetic medications in the dataset, their
true glycemic staging is unknown to us but are assumed to
be normal in our study. In the US, a substantial proportion
(27.8 %, or 8.1 million of 29.1 million in 2012) of diabetic
patients are undiagnosed [6]. The proportion of undiag-
nosed PreD might even be much higher. However, since a
minimum of 2 years of continuous enrollment was required
for all normal glycemic subjects, we at least know that they
have no evidence of elevated glucose for at least 2 years.
Costs may be assigned to a glycemic stage less severe than
the genuine glycemic level (i.e. assign costs associated
with PreD to the normal glycemic stage, and assign costs
associated with T2D to the PreD or normal glycemic
stage), which may lead to estimation bias. However, our
glycemic staging algorithm utilized all the information
available in the dataset, and has been used in a previously
published study [33].
Our results should be interpreted in light of the study’s
limitations. First and foremost, the use of a retrospective
cohort design prevented us from understanding the causal
effect of BMI on the increase in healthcare costs. Second,
claim reimbursement data were not available in the dataset.
We applied standard cost data derived from external sources
to the utilization recorded in the claims in the MedMining
dataset. The medical costs may be under-estimated since
CMS fee schedules are usually lower than the commercial
insurances, while the average wholesale price used in our
study is likely to be higher than the acquisition cost of
medication. However, our study aims to assess the relative
differences in costs between BMI levels, thus the biasness in
the absolute costs does not affect our findings. Third, veri-
fied enrollment in drug coverage is not available and thus
use of medication may not be fully identified. Fourth, esti-
mation bias may exist. For example, unobserved factors (e.g.
health status) may affect both the availability of BMI and
healthcare costs, and thus lead to sample selection bias.
Also, specific physician disposition may also play a role in
the BMI and cost association. Finally, the findings are based
on data from a single integrated health system caring for
subjects in northern Pennsylvania and may not be general-
izable to larger populations or to other regions at county,
state, or national level in the US.
Regardless of these limitations, our study is the first
analysis to assess the economic burden of being overweight
and obese at different levels of severity, stratified by gly-
cemic stage. Our study has other strengths. First, we fol-
lowed subjects for at least 1 year until the end of a
glycemic stage (within the continuous enrollment in the
health plan), instead of only a 1-year snapshot of data, as
examined in previous studies [25]. Findings from longer
follow-up can provide a more comprehensive evaluation on
the economic burden of obesity, since the healthcare costs
were found to vary by duration of time in the glycemic
stage, particularly for subjects with elevated glucose [13,
34]. Moreover, BMI values were clinically measured in the
current study, while a majority of the published studies
relied on self-reported weight and height. Self-reported
weight and height considerably underestimate the subjects’
measured BMI [35, 36], which leads to systematic bias in
the results. In addition, our study contained detailed
demographic information, such as race, smoking status,
and employment status, which are important confounders
in cost-of-illness studies, but have not been widely cap-
tured and adjusted for in published studies.
5 Conclusions
Higher BMI level is associated with higher annual
healthcare costs within all glycemic stages, after adjusting
for demographic characteristics. The economic burden of
overweight and obesity is higher among subjects with PreD
or T2D. Targeted weight-control programs aimed at
patients with pre-diabetes, or at-risk normal glycemic
subjects, as well as those with frank T2D, should be able to
generate a significant return on investment by effectively
reducing the economic burden of overweight and obesity in
the US. The impact on the health of the individual and the
population is likely even more dramatic.
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18.5 B BMI\ 25 Reference Reference Reference Reference
25 B BMI\ 30 1.09 (1.07–1.11) 1.11 (1.06–1.16) 1.05 (1.03–1.06) 1.16 (1.13–1.20)
30 B BMI\ 35 1.25 (1.22–1.27) 1.35 (1.29–1.43) 1.15 (1.13–1.17) 1.33 (1.29–1.38)
35 B BMI\ 40 1.30 (1.26–1.34) 1.41 (1.32–1.51) 1.23 (1.20–1.26) 1.36 (1.30–1.42)
40 B BMI 1.51 (1.45–1.56) 2.06 (1.89–2.24) 1.28 (1.24–1.32) 1.47 (1.40–1.56)
Age group, years
18–44 Reference Reference Reference Reference
45–64 1.73 (1.7–1.75) 2.40 (2.31–2.5) 1.51 (1.49–1.53) 1.66 (1.62–1.71)
65–74 2.93 (2.84–3.02) 7.25 (6.73–7.81) 2.24 (2.18–2.3) 1.83 (1.75–1.92)
75–84 4.87 (4.66–5.1) 17.35 (15.62–19.27) 2.88 (2.78–2.99) 1.95 (1.82–2.08)
85? 7.61 (6.79–8.52) 34.85 (26.7–45.49) 2.88 (2.62–3.17) 1.91 (1.61–2.27)
Male 1.30 (1.28–1.32) 1.07 (1.04–1.11) 1.35 (1.33–1.36) 1.43 (1.4–1.46)
White race 1.23 (1.17–1.29) 1.15 (1.03–1.3) 1.17 (1.12–1.22) 1.28 (1.19–1.38)
Smoking status
Never smoked Reference Reference Reference Reference
Former smoker 1.29 (1.27–1.32) 1.43 (1.36–1.50) 1.20 (1.18–1.23) 1.32 (1.28–1.36)
Current smoker 1.20 (1.17–1.22) 1.45 (1.39–1.52) 1.15 (1.13–1.17) 1.11 (1.08–1.14)
Other/unknown 1.25 (1.22–1.29) 1.80 (1.67–1.94) 1.22 (1.19–1.25) 1.04 (0.99–1.09)
Employment status
Full-time Reference Reference Reference Reference
Not employed 1.18 (1.15–1.21) 1.19 (1.13–1.25) 1.05 (1.03–1.07) 1.29 (1.24–1.33)
Other/unknown 1.04 (1.02–1.06) 1.10 (1.04–1.16) 1.07 (1.05–1.08) 0.97 (0.94–1)
Covered by HMO
insurance
1.02 (1–1.05) 1.11 (1.05–1.17) 1.00 (0.98–1.02) 1.00 (0.96–1.03)
Stage starting year
2004 Reference Reference Reference Reference
2005 1.10 (1.07–1.13) 1.04 (0.97–1.12) 1.14 (1.11–1.17) 1.11 (1.06–1.16)
2006 1.10 (1.07–1.13) 1.09 (1.02–1.17) 1.11 (1.09–1.14) 1.14 (1.09–1.19)
2007 1.20 (1.16–1.23) 1.12 (1.04–1.2) 1.17 (1.14–1.2) 1.32 (1.26–1.38)
2008 1.20 (1.16–1.24) 1.05 (0.98–1.13) 1.24 (1.21–1.28) 1.26 (1.21–1.32)
2009 1.23 (1.2–1.27) 1.11 (1.04–1.19) 1.30 (1.27–1.34) 1.24 (1.18–1.29)
2010 1.43 (1.37–1.5) 1.43 (1.29–1.59) 1.52 (1.47–1.58) 1.35 (1.26–1.45)
2011 0.56 (0.31–0.99) 0.00 (0.00–0.01) 0.74 (0.46–1.2) 0.81 (0.34–1.92)
Goodness of fit




18.5 B BMI\ 25 Reference Reference Reference Reference
25 B BMI\ 30 1.09 (0.95–1.25) 1.23 (0.86–1.76) 1.09 (0.98–1.23) 1.20 (0.98–1.46)
30 B BMI\ 35 1.09 (0.95–1.25) 1.01 (0.71–1.45) 1.22 (1.09–1.37) 1.19 (0.97–1.45)
35 B BMI\ 40 1.04 (0.9–1.22) 0.89 (0.59–1.33) 1.09 (0.96–1.24) 1.24 (1.00–1.56)









Cost ratio 95 % CI Cost ratio 95 % CI Cost ratio 95 % CI Cost ratio 95 % CI
40 B BMI 1.28 (1.09–1.51) 1.15 (0.75–1.75) 1.26 (1.10–1.44) 1.48 (1.16–1.89)
Age group, years
18–44 Reference Reference Reference Reference
45–64 1.17 (1.06–1.31) 2.09 (1.59–2.77) 1.06 (0.97–1.16) 1.11 (0.94–1.3)
65–74 1.64 (1.4–1.91) 3.94 (2.61–5.94) 1.32 (1.16–1.5) 1.43 (1.14–1.79)
75–84 3.09 (2.59–3.69) 12.71 (7.94–20.36) 1.58 (1.36–1.82) 1.49 (1.15–1.93)
85? 6.68 (4.81–9.27) 37.11 (15.68–87.84) 2.07 (1.58–2.72) 1.94 (1.21–3.12)
Male 1.08 (1–1.17) 0.80 (0.65–0.98) 1.10 (1.03–1.17) 1.29 (1.15–1.44)
White race 1.91 (1.51–2.4) 3.12 (1.7–5.74) 1.47 (1.21–1.78) 1.89 (1.35–2.65)
Smoking status
Never smoked Reference Reference Reference Reference
Former smoker 1.25 (1.15–1.37) 1.41 (1.12–1.76) 1.08 (1.01–1.16) 1.36 (1.2–1.55)
Current smoker 1.25 (1.13–1.39) 1.81 (1.38–2.38) 1.09 (1–1.19) 1.16 (1–1.36)
Other/unknown 0.99 (0.75–1.31) 0.83 (0.4–1.71) 0.82 (0.65–1.04) 1.33 (0.87–2.01)
Employment status
Full-time Reference Reference Reference Reference
Not employed 1.57 (1.38–1.78) 2.36 (1.68–3.31) 1.73 (1.55–1.93) 1.25 (1.03–1.51)
Other/unknown 1.02 (0.91–1.14) 1.27 (0.94–1.71) 1.19 (1.08–1.3) 0.77 (0.66–0.9)
Covered by HMO
insurance
1.02 (0.91–1.15) 1.08 (0.78–1.48) 0.98 (0.89–1.08) 0.98 (0.83–1.16)
Stage starting year
2004 Reference Reference Reference Reference
2005 1.03 (0.87–1.23) 1.50 (0.95–2.35) 1.27 (1.1–1.47) 0.85 (0.65–1.1)
2006 0.99 (0.84–1.16) 1.35 (0.88–2.05) 1.23 (1.08–1.41) 0.82 (0.64–1.05)
2007 0.99 (0.84–1.16) 0.90 (0.59–1.38) 1.22 (1.06–1.4) 0.96 (0.74–1.22)
2008 1.01 (0.85–1.19) 0.94 (0.61–1.43) 1.23 (1.07–1.41) 1.01 (0.79–1.3)
2009 1.20 (1.02–1.41) 1.29 (0.86–1.94) 1.59 (1.39–1.81) 1.00 (0.78–1.28)
2010 1.09 (0.93–1.28) 1.29 (0.85–1.96) 1.32 (1.16–1.51) 0.93 (0.73–1.18)
2011 1.33 (1.09–1.62) 1.49 (0.89–2.49) 1.75 (1.48–2.06) 1.02 (0.76–1.37)
Goodness of fit




18.5 B BMI\ 25 Reference Reference Reference Reference
25 B BMI\ 30 1.11 (1.03–1.20) 1.11 (0.91–1.37) 1.11 (1.04–1.18) 1.14 (1.02–1.27)
30 B BMI\ 35 1.17 (1.09–1.27) 1.09 (0.89–1.34) 1.17 (1.09–1.25) 1.26 (1.13–1.40)
35 B BMI\ 40 1.29 (1.19–1.40) 1.20 (0.96–1.49) 1.22 (1.14–1.31) 1.40 (1.24–1.57)
40 B BMI 1.46 (1.34–1.59) 1.60 (1.27–2.01) 1.27 (1.18–1.37) 1.48 (1.31–1.67)
Age group, years
18–44 reference Reference Reference Reference
45–64 1.33 (1.25–1.41) 1.83 (1.55–2.15) 1.18 (1.12–1.24) 1.22 (1.12–1.33)
65–74 1.73 (1.6–1.87) 3.37 (2.74–4.15) 1.46 (1.37–1.56) 1.12 (1.01–1.25)
75–84 2.79 (2.55–3.04) 7.19 (5.68–9.09) 1.91 (1.77–2.06) 1.19 (1.05–1.35)
85? 3.98 (3.36–4.72) 13.15 (8.34–20.71) 1.72 (1.49–1.99) 1.20 (0.94–1.52)
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